Vascular Interventional Devices: New Avenues For Growth

Manufacturers are finding it harder to innovate in the vascular interventional devices as market and regulatory pressures take their toll. New coronary drug-eluting stents face a difficult challenge with the high bar now set by existing devices, and there have been several recent disappointments in renal denervation, drug-coated balloons, and renal artery stenting; still there are some promising areas, with bioresorbable stents offering perhaps the best prospect among vascular therapies for future blockbuster status.

Last October, interventional cardiologists marked the 25th anniversary of the Transcatheter Cardiovascular Therapeutics (TCT) conference, long recognized as the premier US showcase for new, and often groundbreaking, vascular interventional technologies. The 2013 TCT, held in San Francisco, CA, paid homage, and rightly so, to the amazing progress the field has witnessed over the past 25 years. But this specialty has a well-earned reputation for constantly pushing the bar of innovation, and it’s safe to assume those in attendance at the 2013 meeting were most keenly interested in the progress the field is likely to make over the next 25 years.

And therein lies something of a conundrum. For although interventional medicine has made great strides over the past three decades,...

More from Archive

More from In Vivo

Execs On The Move: June 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By 

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By 

Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.